Cyanotech, Valensa Agree to Settle Long-Standing Patent DisputeCyanotech, Valensa Agree to Settle Long-Standing Patent Dispute
The University of Illinois, which owned the patent, and Valensa, which licensed certain rights under it, alleged the patent method claims covered the manufacturing, marketing and sales of astaxanthin as a nutritional supplement.
November 24, 2014
The parties have agreed to confidential terms of a settlement and anticipate filing a joint motion to dismiss a federal lawsuit and administrative proceeding by Dec. 1, according to a Nov. 13 regulatory filing.
In 2012, U.S. Nutraceuticals LLC (doing business as Valensa International) and the university trustees board sued Cyanotech and its subsidiary Nutrex Hawaii Inc., a provider of supplements, alleging infringement of patent 5,527,533.
The ‘533 patent is described as a method for ameliorating certain diseases, injuries or damage through the administration of astaxanthin, according to the Securities and Exchange Commission filing. Cyanotech, whose microalgae-derived products are produced on the Kona Coast of Hawaii, markets astaxanthin as a natural health supplement.
Cyanotech later petitioned the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) to review the patent’s validity. On Dec. 19, 2013, PTAB began an inter partes review of 18 of 27 claims within the patent, according to the filing.
Plaintiffs’ request for injunctive relief was recently rendered moot because the 18-year-old patent at issue expired on Oct. 27, 2014, according to regulatory filings.
The University of Illinois, which owned the patent, and Valensa, which licensed certain rights under it, alleged the patent method claims covered the manufacturing, marketing and sales of astaxanthin as a nutritional supplement, according to regulatory filings. Cyanotech denied the allegations and filed counterclaims in the federal lawsuit.
The parties invested a significant amount of time and resources litigating the case, with discovery on factual issues concluding in July. Last year, Cyanotech’s general and administrative expenses rose by UDS $666,000 or 17 percent, thanks in part to an increase in legal fees of $520,000, the company disclosed in a June 27, 2014 regulatory filing.
A trial in the U.S. District Court for the Middle District of Florida was scheduled for March 2, 2015, and the PTAB was expected to issue a ruling by Dec. 19, 2014.
Cyanotech and Valensa did not respond to requests for comment on the settlement.
About the Author(s)
You May Also Like
Beyond vaginal microbiota: Emotional well-being, gut health support – white paperNov 22, 2023
EPA and DHA help distance runners avoid muscle damage in sports nutrition studyDec 07, 2023
Generation Alpha emerges as a sophisticated and desirable target marketDec 07, 2023
6 reasons prebiotics may be more important than probioticsDec 06, 2023